on! PLUS Just Got FDA Authorized: What You Need to Know

TL;DR

On May 8, 2025, the FDA authorized multiple on! PLUS nicotine pouch products through the premarket tobacco product application (PMTA) pathway. This authorization allows Helix Innovations LLC to legally market these specific products to adults 21 and older in the United States. The decision represents a significant regulatory milestone for the on! brand and provides clarity for retailers and consumers seeking tobacco products that have undergone federal review.

The FDA's Authorization Decision

The FDA's premarket tobacco product application process requires manufacturers to demonstrate that marketing their products is appropriate for the protection of public health. On May 8, 2025, the FDA concluded this review for specific on! PLUS products and issued marketing granted orders.

This authorization covers multiple nicotine strengths within the on! PLUS line. The products join a growing list of nicotine pouches that have successfully navigated the PMTA pathway, which became mandatory for all deemed tobacco products under the Family Smoking Prevention and Tobacco Control Act.

According to FDA tobacco product regulations, authorization means the agency determined that permitting these products on the market serves public health interests based on the totality of evidence submitted. This is not an endorsement of safety—all tobacco products carry inherent risks.

What FDA Authorization Actually Means

Consumers often misunderstand what FDA authorization signifies. The term "authorized" differs fundamentally from "approved." The FDA does not approve tobacco products as safe or beneficial. Instead, authorization indicates:

• The manufacturer submitted comprehensive data on product design, ingredients, manufacturing, and potential health impacts
• The FDA reviewed this data and determined that marketing the product is appropriate for public health protection
• The product can be legally sold in the United States to adults 21 and older
• The manufacturer must comply with ongoing reporting requirements and post-market surveillance

The FDA's nicotine pouch landing page maintains an updated list of all authorized products. Consumers seeking products that have undergone federal review can reference this resource.

Authorized on! PLUS Products

The May 8, 2025 authorization covers these on! PLUS variants:

Each authorized product received its own marketing granted order with specific parameters. Manufacturers cannot modify formulations, packaging, or marketing without additional FDA review.

Impact on Retailers and Consumers

For retailers, FDA authorization provides legal certainty. Products with marketing granted orders can be stocked without concern about potential enforcement actions. Retailers must still:

• Verify purchasers are 21 years of age or older
• Comply with state and local tobacco sales regulations
• Follow FDA marketing and advertising requirements
• Maintain required records

For consumers 21 and older, authorization means these specific on! PLUS products underwent rigorous federal review. However, "authorized" does not mean "recommended" or "safe." Adults considering nicotine pouches should understand that nicotine is addictive and these products are not smoking cessation devices.

The Broader Regulatory Landscape

The on! PLUS authorization comes amid ongoing PMTA reviews across the nicotine pouch category. According to FDA tobacco product data, the agency received thousands of applications for deemed tobacco products, including numerous nicotine pouch variants.

Many products remain in "pending review" status. Manufacturers cannot market products with pending applications unless they were commercially marketed as of August 8, 2016, and submitted timely PMTAs. The FDA continues issuing both marketing granted orders and marketing denial orders as it works through the application backlog.

State-Level Considerations

While FDA authorization permits federal marketing, state and local jurisdictions maintain independent regulatory authority. Some states have:

• Flavor restrictions that may affect certain authorized products
• Additional age verification requirements beyond federal standards
• Taxes specific to oral nicotine products
• Retail licensing requirements for tobacco sales

Consumers and retailers should verify compliance with local regulations even when products carry FDA authorization.

What Happens Next

Helix Innovations LLC must now:

• Comply with ongoing reporting obligations to the FDA
• Maintain manufacturing standards that match authorized specifications
• Monitor and report any adverse events associated with authorized products
• Submit additional applications for any product modifications

The FDA may conduct post-market surveillance and could revoke authorization if new evidence demonstrates public health concerns. The agency's commitment to ongoing evaluation appears in multiple FDA press announcements regarding tobacco product oversight.

Industry Implications

The on! PLUS authorization signals continued FDA engagement with the nicotine pouch category. Manufacturers throughout the industry are watching these decisions closely as they await determinations on their own pending applications.

Authorization does not guarantee market success, but it removes a significant regulatory barrier. The on! brand now competes with other authorized products in a category experiencing substantial growth among adult nicotine users 21 and older.

Understanding Your Options

Adults 21 and older considering nicotine pouches should recognize that multiple factors beyond FDA authorization matter:

• Nicotine strength appropriate for individual tolerance
• Format and pouch size preferences
• Flavor availability within legal parameters
• Pricing that fits personal budgets

FDA authorization provides regulatory clarity but does not address individual suitability. CDC tobacco resources offer additional information about nicotine products and their health implications.

The Bottom Line

The May 8, 2025 FDA authorization of on! PLUS products represents a major regulatory achievement for Helix Innovations LLC and provides consumers 21 and older with federally reviewed options. However, authorization is not approval, and these products are not without risk.

Retailers gain legal certainty for stocking these specific SKUs. Consumers gain transparency about products that underwent federal review. The nicotine pouch category continues evolving within a regulatory framework designed to balance adult access with public health protection.

For the most current information on authorized nicotine pouch products, consumers and retailers should consult the FDA's official tobacco products page regularly, as authorization status can change based on new evidence or regulatory determinations.